Officer Files to Sell Another $1.02M in Stock, Extending Recent Selling Trend
ANAB has more than doubled off its 52-week low of $11.402.
Summary
AnaptysBio officer Dennis Mulroy has filed to sell an additional $1.02 million in company stock, continuing a recent pattern of significant insider selling.
Key Events · Ownership and Investor Activity · ANAB
-
Officer Files Intent to Sell
Dennis Mulroy, an officer at AnaptysBio, has filed a Form 144 to sell 20,000 shares of common stock, valued at approximately $1,017,250.
-
Continuation of Insider Selling
This filing extends a recent trend of significant insider distribution by Mulroy, who has filed multiple Form 144s in the past few days and sold over $6.78 million in shares over the last three months.
-
Conflicting Signals with Repurchase Program
The ongoing officer selling occurs shortly after the company announced a $100 million share repurchase program, which could create investor uncertainty regarding management's outlook.
Analysis · ANAB · Life Sciences
AnaptysBio officer Dennis Mulroy has filed a Form 144 to sell an additional $1.02 million worth of common stock. This filing is part of a clear and ongoing pattern of insider selling by Mulroy, who has filed multiple Form 144s in recent days and sold over $6.78 million in shares over the past three months. This sustained distribution by an officer could be viewed negatively by investors, especially as it occurs shortly after the company announced a $100 million share repurchase program, creating conflicting signals about management's confidence and capital allocation strategy.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ANAB was trading at $51.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $11.40 to $72.36. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.